secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corbus Pharmaceuticals Holdings, Inc. (CRBP)
CIK:        0001595097
Form:       8-K
Filed at:   2026-07-06T12:15:35+00:00
Accession:  0001193125-26-295622
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corbus appoints Leonardo Viana Nicacio as CMO; base salary $545K, equity $2.1M
------------------------------------------------------------------------------

- Dr. Nicacio appointed CMO effective Aug 3, 2026; base salary $545K, target bonus up to 40%, equity inducement awards of $2.1M.
- He brings ADC and HPV-driven oncology experience, previously CMO at Protara, VP at Seagen (TIVDAK), and roles at AstraZeneca, Flatiron Health.
- Corbus expects to initiate TEMPO-1 registrational study of CRB-701 in 2L OPSCC summer 2026; topline CANYON-1 obesity study data late summer 2026.
- Employment agreement for 2 years, includes non-compete (6 months post) and non-solicitation (12 months post), severance provisions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595097/000119312526295622/0001193125-26-295622-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595097/000119312526295622/crbp-20260702.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-295622

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer